The project has historically studied the action of tumor suppressor genes, and is based on the premise that tumor suppressors reveal key regulatory nodes in growth control processes and the strategies nature uses to combat cancer. Based on our observation that certain oncogenes promote apoptosis through p53, we initially explored the mechanisms by which p53 suppressed apoptosis and how disruption of p53 network components promoted tumorigenesis and impacted therapy response. Taking advantage of program collaborations, we later established how p53 loss sustains tumorigenesis and, by combining oncogenomics, functional genomics, and in vivo genetic screens, established the functional relevance of many cancer drivers. Over the last funding cycle, we expanded our efforts towards understanding how tumor suppressor loss is required for tumor maintenance, showing that re-establishing tumor suppressor networks can have profound and distinct anti- proliferative effects, even in advanced cancers. This evolution spawned our current interest in ?tumor maintenance genes? ? genes needed to sustain cancer progression ? and stimulated the development of new mouse models that enable suppression and/or reactivation of gene function at different stages of disease. Moving forward, the project will focus on the identification and characterization of tumor suppressor and tumor maintenance genes in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) ? two primary liver cancers for which genomic studies have identified few ?druggable? cancer drivers, and for which no effective therapies exist. As such, we now propose to characterize how mutations in certain chromatin-modifying genes ? which are common in human tumors but are poorly understood - drive tumor initiation and maintenance, and to implement new genetic and genomic tools to identify and validate therapeutic targets for primary liver cancers driven by these altered gene products. Our approach combines mouse models, genetic tools, and cancer genomics in a coordinated manner that enables the comprehensive interrogation of tumor suppressor and tumor maintenance network, and benefits from multiple interactions with other projects and cores. The project will produce a more complete understanding of how primary liver cancers are initiated and maintained while simultaneously validating new therapeutic targets for these diseases. As such, our project addresses an urgent and unmet clinical need.
This project explores the action of tumor suppressor and tumor maintenance genes in primarily liver cancers ? tumor types for which there is an unmet clinical need. It combines mouse models, genetic tools, and cancer genomics in a coordinated manner that enables the interrogation of tumor suppressor and tumor maintenance networks in a comprehensive way. We expect the proposed work to produce molecular insights into a new class of tumor suppressors that impact chromatin, and identify novel targets to exploit mutations in these genes.
| Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348 |
| Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983 |
| Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8 |
| Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res : |
| On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139 |
| Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381 |
| Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368 |
| Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114 |
| Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277 |
| Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6 |
Showing the most recent 10 out of 610 publications
